Breaking News

Ocera Appoints Chief Development Officer

August 12, 2014

Patni brings leadership experience from Roche, Novartis and Pfizer

Rajiv Patni, M.D. has been appointed chief development officer at Ocera Therapeutics, Inc., effective September 2, 2014. Dr. Patni previously served as senior vice president for Actelion U.S. He also served as vice president at Roche and held leadership positions at Novartis and Pfizer.
 
"I am delighted to have Rajiv join our management team and expect that he will make significant contributions to the development of OCR-002," said Linda Grais, M.D., chief executive officer of Ocera. "Rajiv has been involved in over 15 clinical development programs, across several therapeutic areas, including acute care indications. Rajiv also served as an academic physician and trained in internal medicine and cardiology. Rajiv's experience both in the clinic and in industry will be an invaluable asset to Ocera."
 

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity